The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow's oncologists
The use of CDK4/6 inhibitors in combination with endocrine therapy (aromatase inhibitors and fulvestrant) allowed us to radically change our understanding of opportunities in the treatment of hormone-positive HER2-negative advanced breast cancer and determine optimal therapy sequencing. The results...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Girji |
| Almmustuhtton: |
ABV-press,
2020-06-01T00:00:00Z.
|
| Fáttát: | |
| Liŋkkat: | Connect to this object online. |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Interneahtta
Connect to this object online.3rd Floor Main Library
| Hildobáiki: |
A1234.567 |
|---|---|
| Njađus 1 | Oažžumis |